Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from CSPC Pharmaceutical Group ( (HK:1093) ) is now available.
CSPC Pharmaceutical Group has received U.S. Food and Drug Administration approval for an Investigational New Drug application covering SYS6051, an antibody-drug conjugate targeting tissue factor on tumor cells, enabling clinical trials in the U.S. SYS6051 also secured clearance from China’s National Medical Products Administration in April 2026 for clinical trials in advanced solid tumors.
Preclinical studies showed SYS6051 delivered strong anti-tumor activity across various cancers, supporting expectations of favorable therapeutic effects as human trials begin. The dual approvals in the U.S. and China strengthen CSPC’s oncology pipeline and global R&D footprint, potentially enhancing its competitive position in antibody-drug conjugates and expanding future treatment options for patients with advanced solid tumors.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$13.05 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company focused on developing innovative therapies, including biologics and oncology drugs. The group operates through multiple subsidiaries and targets major global markets, with its shares listed on the Stock Exchange of Hong Kong under stock code 1093.
Average Trading Volume: 102,317,891
Technical Sentiment Signal: Buy
Current Market Cap: HK$101.3B
For a thorough assessment of 1093 stock, go to TipRanks’ Stock Analysis page.